19,289 Shares in TransMedics Group, Inc. $TMDX Bought by Corient Private Wealth LP

Key Points

• Corient Private Wealth LP purchased 19,289 TransMedics Group shares worth approximately $1.28 million, while institutional investors and hedge funds collectively own 99.67% of the company.
• Analyst sentiment is mixed: six analysts rate TMDX a Buy, six rate it Hold, and one rates it Sell. The consensus rating is Hold, with an average price target of $124.18.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above estimates, but earnings per share of $0.44 missed the $0.50 consensus forecast.

Corient Private Wealth LP bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 19,289 shares of the company's stock, valued at approximately $1,281,000. Corient Private Wealth LP owned about 0.06% of TransMedics Group as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Freestone Grove Partners LP bought a new position in TransMedics Group in the 2nd quarter worth about $235,000. Odyssean LLC boosted its stake in TransMedics Group by 191.9% in the 2nd quarter. Odyssean LLC now owns 12,814 shares of the company's stock worth $851,000 after purchasing an additional 8,424 shares during the period. Man Group plc purchased a new position in TransMedics Group during the 2nd quarter valued at about $752,000. Jupiter Topco LLC purchased a new position in TransMedics Group in the second quarter valued at about $1,014,000. Finally, Ancora Advisors LLC bought a new position in shares of TransMedics Group in the 2nd quarter valued at approximately $33,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on TMDX. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $124.00 target price on shares of TransMedics Group in a report on Tuesday, June 30th. TD Cowen reaffirmed a "buy" rating and set a $120.00 price objective on shares of TransMedics Group in a research note on Wednesday, July 1st. UBS Group reduced their target price on TransMedics Group from $80.00 to $77.00 and set a "neutral" rating on the stock in a report on Wednesday, August 5th. Weiss Ratings raised TransMedics Group from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday. Finally, Zacks Research cut TransMedics Group from a "hold" rating to a "strong sell" rating in a report on Monday, July 6th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $124.18.

TransMedics Group Price Performance

Shares of TMDX stock opened at $89.98 on Friday. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The firm has a market cap of $3.11 billion, a price-to-earnings ratio of 23.13 and a beta of 1.90. The stock has a 50-day moving average price of $80.14 and a 200 day moving average price of $92.21. TransMedics Group, Inc. has a 12 month low of $60.10 and a 12 month high of $156.00.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). The business had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The company's quarterly revenue was up 20.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.92 earnings per share. Research analysts expect that TransMedics Group, Inc. will post 1.46 EPS for the current year.

Insiders Place Their Bets

In related news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the transaction, the director directly owned 16,642 shares of the company's stock, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source